COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia

Schizophrenia Research

Volumn 90, Issue 1-3, 2007, Pages 86-96

  Woodward, Neil D ^a   Jayathilake, Karu ^b   Meltzer, Herbert Y ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Catechol O methyltransferase; Clozapine; Neuropsychology; Pharmacogenetics; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; CLOZAPINE; DOPAMINE; METHIONINE; VALINE;

ADULT; ARTICLE; ATTENTION; COGNITION; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENERAL CONDITION IMPROVEMENT; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PHARMACOGENETICS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; VERBAL BEHAVIOR; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CLOZAPINE; COGNITION DISORDERS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MEMORY, SHORT-TERM; METHIONINE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROBLEM SOLVING; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME; VALINE;

EID: 33846624143     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.10.002     Document Type: Article

References (66)

1. Aalto S., Bruck A., Laine M., Nagren K., and Rinne J.O. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J. Neurosci. 25 (2005) 2471-2477
2. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., Hwang D.R., Keilp J., Kochan L., Van Heertum R., Gorman J.M., and Laruelle M. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22 (2002) 3708-3719
3. Axelrod J., and Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 233 (1958) 702-705
4. Barch D.M., and Carter C.S. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr. Res. 77 (2005) 43-58
5. Bartholomeusz C.F., Box G., Van Rooy C., and Nathan P.J. The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans. J. Psychopharmacol. 17 (2003) 9-15
6. Benton A.L. Differential behavioral effects of frontal lobe disease. Neuropsychologia 6 (1968) 53-60
7. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J.H., Mattay V.S., Bellomo A., Scarabino T., Weinberger D.R., and Nardini M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 161 (2004) 1798-1805
8. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J., Kunz M., Chakos M., Cooper T.B., Horowitz T.L., and Lieberman J.A. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159 (2002) 1018-1028
9. Bilder R.M., Volavka J., Czobor P., Malhotra A.K., Kennedy J.L., Ni X., Goldman R.S., Hoptman M.J., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Kunz M., Chakos M., Cooper T.B., and Lieberman J.A. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol. Psychiatry 52 (2002) 701-707
10. Boone K.B., Ponton M.O., Gorsuch R.L., Gonzalez J.J., and Miller B.L. Factor analysis of four measures of prefrontal lobe functioning. Arch. Clin. Neuropsychol. 13 (1998) 585-595
11. Brozoski T.J., Brown R.M., Rosvold H.E., and Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205 (1979) 929-932
12. Bruder G.E., Keilp J.G., Xu H., Shikhman M., Schori E., Gorman J.M., and Gilliam T.C. Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol. Psychiatry 58 11 (2005) 901-907
13. Buchanan R.W., Holstein C., and Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry 36 (1994) 717-725
14. Buschke H., and Fuld P.A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24 (1974) 1019-1025
15. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., and Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75 (2004) 807-821
16. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148 (1991) 1474-1486
17. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S., and Grasby P.M. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378 (1995) 180-182
18. Doran A.R., Boronow J., Weinberger D.R., Wolkowitz O.M., Breier A., and Pickar D. Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. Neuropsychopharmacology 1 (1987) 25-32
19. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., and Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6917-6922
20. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., and Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9991-9996
21. Goldberg T.E., Bigelow L.B., Weinberger D.R., Daniel D.G., and Kleinman J.E. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am. J. Psychiatry 148 (1991) 78-84
22. Goldberg T.E., Egan M.F., Gscheidle T., Coppola R., Weickert T., Kolachana B.S., Goldman D., and Weinberger D.R. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry 60 (2003) 889-896
23. Goldman-Rakic P.S., Muly III E.C., and Williams G.V. D(1) receptors in prefrontal cells and circuits. Brain Res. Brain Res. Rev. 31 (2000) 295-301
24. Granon S., Passetti F., Thomas K.L., Dalley J.W., Everitt B.J., and Robbins T.W. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J. Neurosci. 20 (2000) 1208-1215
25. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., and Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry 34 (1993) 702-712
26. Harvey P.D., Siu C.O., and Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology 172 3 (2004) 324-332
27. Heaton R.K. Wisconsin Card Sortin Test (WCST) (1980), Psychological Assessment Resources, Odessa, FL
28. Ho B.C., Wassink T.H., O'Leary D.S., Sheffield V.C., and Andreasen N.C. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol. Psychiatry 10 (2005) 287-298
29. Hwang R., Takahiro S., De Luca V., Muller D.J., Ni X., Macciardi F., Potkin S., Lieberman J.A., Meltzer H.Y., and Kennedy J.L. Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology 181 (2005) 179-187
30. Joober R., Gauthier J., Lal S., Bloom D., Lalonde P., Rouleau G., Benkelfat C., and LaBelle A. Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test. Arch. Gen. Psychiatry 59 (2002) 662-663
31. Kenny J.T., and Meltzer H.Y. Attention and higher cortical functions in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 3 (1991) 269-275
32. Kimberg D.Y., Aguirre G.K., Lease J., and D'Esposito M. Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI. Hum. Brain Mapp. 12 (2001) 246-257
33. Kuroki T., Meltzer H.Y., and Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288 (1999) 774-781
34. Lee M.A., Jayathilake K., and Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr. Res. 37 (1999) 1-11
35. Malhotra A.K., Kestler L.J., Mazzanti C., Bates J.A., Goldberg T., and Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am. J. Psychiatry 159 (2002) 652-654
36. Mattay V.S., Callicott J.H., Bertolino A., Heaton I., Frank J.A., Coppola R., Berman K.F., Goldberg T.E., and Weinberger D.R. Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 12 (2000) 268-275
37. Mattay V.S., Tessitore A., Callicott J.H., Bertolino A., Goldberg T.E., Chase T.N., Hyde T.M., and Weinberger D.R. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann. Neurol. 51 (2002) 156-164
38. Mattay V.S., Goldberg T.E., Fera F., Hariri A.R., Tessitore A., Egan M.F., Kolachana B., Callicott J.H., and Weinberger D.R. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6186-6191
39. Maxwell S.E., and Delaney H.D. An introduction to multilevel models for within-subjects designs. Designing Experiments and Analyzing Data: A Model Comparison Perspective (2004), Lawrence Erlbaum Associates Publishers, New Jersey 763-820
40. Meltzer H.Y. Action of atypical antipsychotics. Am. J. Psychiatry 159 (2002) 153-154
41. Meltzer H.Y., and Sumiyoshi T. Atypical antipsychotic drugs improve cognition in schizophrenia. Biol. Psychiatry 53 (2003) 265-267
42. Meyer-Lindenberg A., Kohn P.D., Kolachana B., Kippenhan S., McInerney-Leo A., Nussbaum R., Weinberger D.R., and Berman K.F. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 8 (2005) 594-596
43. Miyake A., Friedman N.P., Emerson M.J., Witzki A.H., Howerter A., and Wager T.D. The unity and diversity of executive functions and their contributions to complex "Frontal Lobe" tasks: a latent variable analysis. Cognit. Psychol. 41 (2000) 49-100
44. Newcombe F. Missile Wounds of the Brain (1969), Oxford University Press, New York
45. Owen A.M. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 10 (2004) 525-537
46. Peterson L.R., and Peterson M.J. Short-term retention of individual verbal items. J. Exp. Psychol. 58 (1959) 193-198
47. Phillips A.G., Ahn S., and Floresco S.B. Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J. Neurosci. 24 (2004) 547-553
48. Postle B.R. Delay-period activity in the prefrontal cortex: one function is sensory gating. J. Cogn. Neurosci. 17 (2005) 1679-1690
49. Potkin S.G., Fleming K., Jin Y., and Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J. Clin. Psychopharmacol. 21 (2001) 479-483
50. Purdon S.E., LaBelle A., and Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr. Res. 48 (2001) 57-67
51. Roberts A.C., De Salvia M.A., Wilkinson L.S., Collins P., Muir J.L., Everitt B.J., and Robbins T.W. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J. Neurosci. 14 (1994) 2531-2544
52. Rosa A., Peralta V., Cuesta M.J., Zarzuela A., Serrano F., Martinez-Larrea A., and Fananas L. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am. J. Psychiatry 161 (2004) 1110-1112
53. Sakai K., Rowe J.B., and Passingham R.E. Active maintenance in prefrontal area 46 creates distractor-resistant memory. Nat. Neurosci. 5 (2002) 479-484
54. Stefanis N.C., Van Os J., Avramopoulos D., Smyrnis N., Evdokimidis I., Hantoumi I., and Stefanis C.N. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biol. Psychiatry 56 (2004) 510-515
55. Stuss D.T., Kaplan E.F., Benson D.F., Weir W.S., Chiulli S., and Sarazin F.F. Evidence for the involvement of orbitofrontal cortex in memory functions: an interference effect. J. Comp. Physiol. Psychol. 96 (1982) 913-925
56. Tsai S.J., Yu Y.W., Chen T.J., Chen J.Y., Liou Y.J., Chen M.C., and Hong C.J. Association study of a functional catechol-O-methyltransferase-gene polymorphism and cognitive function in healthy females. Neurosci. Lett. 338 (2003) 123-126
57. Tunbridge E.M., Bannerman D.M., Sharp T., and Harrison P.J. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J. Neurosci. 24 (2004) 5331-5335
58. Wagner M., Quednow B.B., Westheide J., Schlaepfer T.E., Maier W., and Kuhn K.U. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 30 (2005) 381-390
59. Wechsler D. Wechsler Intelligence Scale for Children-Revised (WISC-R) Manual (1974), Psychological Corporation, New York
60. Wechsler D. Wechsler Adult Intelligence Scale-Revised (WAIS-R) (1981), The Psychological Corporation, Harcourt Brace Jovanovich, Cleveland
61. Weickert T.W., Goldberg T.E., Mishara A., Apud J.A., Kolachana B.S., Egan M.F., and Weinberger D.R. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry 56 (2004) 677-682
62. Weinberger D.R., Berman K.F., and Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiatry 45 (1988) 609-615
63. Weinberger D.R., Egan M.F., Bertolino A., Callicott J.H., Mattay V.S., Lipska B.K., Berman K.F., and Goldberg T.E. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry 50 (2001) 825-844
64. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. (2005) 1-16
65. Youngren K.D., Inglis F.M., Pivirotto P.J., Jedema H.P., Bradberry C.W., Goldman-Rakic P.S., Roth R.H., and Moghaddam B. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20 (1999) 403-412
66. Zahn T.P., Pickar D., and Haier R.J. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr. Res. 13 (1994) 133-144